Author

D.-W. Kim

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:cell type annotation· 4 Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2

Frequent Co-Authors

K.-B. Kim· 4 shared K.-S. Park· 4 shared Y. Kim· 3 shared J.-I. Park· 2 shared A. Bottrill· 1 shared A. C. Singer· 1 shared A. Kabra· 1 shared A. Voshall· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

K.-B. Kim

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Pan-cancer analysis reveals multifaceted roles of retrotransposon-fusion RNAs

B. Lee, J. Park, A. Voshall, E. Maury, Y. Kang, Y. J. Kim, J.-Y. Lee, H.-R. Shim, H.-J. Kim, J.-W. Lee, M.-H. Jung, S.-C. Kim, H. B. K. Chu, D.-W. Kim, M. Kim, , E. A. Lee

The paper identifies cancer-specific transposon-fusion RNAs across 34 cancer types and finds they are associated with tumor suppressors and oncogenes, and can activate T-cells.

bioRxiv · Oct 16, 2023 · PreprintCancer Biology

Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer

Y. Seo, S. Zhang, J. Jang, K.-P. Ko, K.-B. Kim, Y. Huang, D.-W. Kim, B. Kim, G. Zou, J. Zhang, S. Jun, W. Chu, N. A. Kirk, Y. E. Hwang, Y. H. Ban, , J.-I. Park

This study shows that CRACD, an actin regulator, suppresses neuroendocrine plasticity and immune evasion in SCLC by modulating NOTCH1 and EZH2 pathways, suggesting EZH2 blockade as a potential therapy.

bioRxiv · Feb 15, 2023Cancer Biology

WNT5A-RHOA axis is a new vulnerability in small-cell lung cancer

K.-B. Kim, D.-W. Kim, Y. Kim, J. Tang, N. Kirk, Y. Gan, B. Fang, J.-I. Park, Y. Zheng, K.-S. Park

This study identifies the WNT5A-RHOA axis as a critical driver of small-cell lung cancer, offering new therapeutic targets and insights into WNT signaling heterogeneity.

bioRxiv · Apr 14, 2022 · PreprintCancer Biology

Unique role and vulnerability of EP300 KIX domain in small-cell lung cancer

K.-B. Kim, A. Kabra, D.-W. Kim, Y. Xue, P.-C. Hou, Y. Zhou, L. Miranda, X. Shi, T. P. Bender, J. H. Bushweller, K.-S. Park

The paper identifies the EP300 KIX domain as a critical driver of SCLC and shows that targeting this domain can inhibit tumor growth.

bioRxiv · Jun 3, 2021 · PreprintCancer Biology

Impact of sulfamethoxazole on a riverine microbiome

C. Borsetto, S. Raguideau, E. R. Travis, D.-W. Kim, D.-H. Lee, A. Bottrill, R. Stark, L. Song, C.-J. Cha, J. Pearson, C. Quince, A. C. Singer, E. M. H. Wellington

This study investigates the impact of sub-lethal sulfamethoxazole concentrations on river bacterial microbiomes using a flume system and omics approaches, finding limited effects on the resistome and no changes in ARG expression.

bioRxiv · Apr 1, 2021Microbiology

FGFR1 is critical for Rbl2 loss-driven tumor development and requires PLCG1 activation for continued growth of small cell lung cancer

K.-B. Kim, Y. Kim, D.-W. Kim, K.-S. Park

This study identifies FGFR1's role in SCLC development and growth, showing its dependency on Rbl2 loss and PLCG1 activation.

Cancer Research · Nov 13, 2020Peer-reviewedCancer Biology